Description
GLP-3 is a potent, next-generation “triple-agonist” peptide (targeting GLP-1, GIP, and Glucagon receptors) designed for significant weight loss and type 2 diabetes management. It achieves up to 24-28% body weight reduction in trials by suppressing appetite, slowing digestion, and increasing energy expenditure
